FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

	OMB APPRO	VAL							
	OMB Number:	3235-0287							
	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* McMahon Gerald PhD					2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [CLDX]									(Check all		olicable) ctor	109	Person(s) to Issuer 10% Owner		
(Last) (First) (Middle) C/O CELLDEX THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 11/01/2018										Officer (give title below)		Oth belo	er (specify w)	
53 FRONTAGE ROAD, SUITE 220					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) HAMPT(ON N.	0)8827										X	erson eporting						
(City)	(Si	ate) (Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)					Execut ay/Year) if any		A. Deemed kecution Date, any lonth/Day/Year)					curities Acquired (A) osed Of (D) (Instr. 3, 4			ıd 5)	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect	
						Code	v	Amount	(A (E	A) or D)	Price		Transa	action(s) 3 and 4)		(11311. 4)				
Common Stock, par value \$0.001 11/01					/2018				F		2,888		D \$0.31		145 183,521(1)(2)		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date Execution Date, if any (Month/Day/Year)				saction le (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expira (Monti	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amour or Numbe of Title Shares		-		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)				

Explanation of Responses:

1. On November 28, 2016, in connection with the Reporting Person's employment severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock. par value \$0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018.

2. Pursuant to the Severance Agreement, on November 1, 2018, the Issuer issued 5,466 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,888 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.

> /s/ Samuel B. Martin, attorneyin-fact for Gerald McMahon

11/02/2018

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.